Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 12 pages · English
• StemSmart™ Special Access Program: Treating patients with Fistulising Crohn’s Disease, with multiple patients approved and undergoing treatment with StemSmart™ therapeutic (and initial results, demonstrating “Clinical Response” following the Reporting Period). • Phase 2 Clinical Trial Preparation: Real-world clinical data generated under the Special Access Program continues to inform Phase 2 cli
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Successful Clinical Results Achieved under Special Access
- Trading Halt
- Fourth Patient Commences StemSmart MSC Treatment
- 2025 Annual Report & Appendix 4E
- Previous StemSmart Studies Support Renal Transplantation
Later from Neuroscientific Biopharmaceuticals
- Half Yearly Report and Accounts
- Remarkable Results from Patients treated with StemSmart
- 2026 Annual Report & Appendix 4E
- Leading CRO Appointed for Phase 2 Crohn's Trial
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals